Oral [60]fullerene reduces neuroinflammation to alleviate Parkinson's disease via regulating gut microbiome
Xue Li, Ruijun Deng, Jie Li, Hui Li, Zhe Xu, Lei Zhang, Linyin Feng, Chunying Shu, Mingming Zhen, Chunru Wang
Abstract
Our findings suggest that OFO is a safe-to-use, easy-to-apply, and prospective candidate for PD treatment in clinic, opening a therapeutic window for neuroinflammation-triggered neurodegeneration.
Topics & Concepts
NeuroinflammationNeurodegenerationWestern blotParkinson's diseaseMPTPChemistryPharmacologyMedicinePathologyBiochemistryDiseaseGeneFullerene Chemistry and ApplicationsIntensive Care Unit Cognitive DisordersTryptophan and brain disorders